Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry by Sato-Kuwabara, Yukie et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Evaluation of gene amplification and protein expression of 
HER-2/neu in esophageal squamous cell carcinoma using 
Fluorescence in situ Hybridization (FISH) and 
immunohistochemistry
Yukie Sato-Kuwabara*†1, José I Neves†1, José HTG Fregnani†2, 
Rubens A Sallum†3 and Fernando A Soares†1
Address: 1Department of Anatomic Pathology, Hospital AC Camargo, Rua Antônio Prudente, 211, 1o. andar, São Paulo, SP, CEP: 01509-010, 
Brazil, 2Department of Morphology, School of Medical Sciences of Santa Casa of São Paulo, Rua Dr. Cesário Motta Jr., 61, São Paulo, SP, CEP: 
01221-020, Brazil and 3Department of Abdominal Surgery, Hospital AC Camargo, Rua Antônio Prudente, 211, 1o. andar, São Paulo, SP, CEP: 
01509-010, Brazil
Email: Yukie Sato-Kuwabara* - yukiesato@gmail.com; José I Neves - bio_neves@uol.com.br; José HTG Fregnani - mdfregnani@terra.com.br; 
Rubens A Sallum - rubenssallum@globo.com; Fernando A Soares - soaresfernando@terra.com.br
* Corresponding author    †Equal contributors
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is the sixth most frequent neoplasia in Brazil. It is usually associated
with a poor prognosis because it is often at an advanced stage when diagnosed and there is a high frequency of lymph node
metastases. It is important to know what prognostic factors can facilitate diagnosis, optimize therapeutic decisions, and improve
the survival of these patients. A member of the epidermal growth factor receptor (EGFR) family, c-erbB-2, has received much
attention because of its therapeutic implications; however, few studies involving fluorescence in situ hybridization (FISH) analysis
of HER-2/neu gene amplification and protein expression in ESCC have been conducted. The aim of this study was to verify the
presence of HER-2/neu gene amplification using FISH, and to correlate the results with immunohistochemical expression and
clinical-pathological findings.
Methods: One hundred and ninety-nine ESCC cases were evaluated using the Tissue Microarray (TMA) technique. A polyclonal
antibody against c-erbB-2 was used for immunohistochemistry. Analyses were based on the membrane staining pattern. The
results were classified according to the Herceptest criteria (DAKO): negative (0/1+), potential positive (2+) and positive (3+).
The FISH reactions were performed according to the FISH HER2 PharmDx (DAKO) protocol. In each case, 100 tumor nuclei
were evaluated. Cases showing a gene/CEN17 fluorescence ratio ≥ 2 were considered positive for gene amplification.
Results: The c-erbB-2 expression was negative in 117/185 cases (63.2%) and positive in 68 (36.8%), of which 56 (30.3%) were
2+ and 12 (6.5%) were 3+. No significant associations were found among protein expression, clinicopathological data and overall
survival. Among the 47 cases analyzed, 38 (80.9%) showed no gene amplification while 9 (19.1%) showed amplification, as
demonstrated by FISH. Cases that were negative (0/1+) and potential positive (2+) for c-erbB-2 expression by
immunohistochemistry showed no gene amplification. However, all cases with gene amplification were positive (3+) by
immunohistochemistry. According to univariate analysis, there was a significant difference (p = 0.003) in survival rates when
cases with and without HER-2/neu amplification were compared.
Conclusion: Our data demonstrate the correspondence between gene amplification and protein expression of HER-2/neu.
Gene amplification is an indicator of poor prognosis in ESCC.
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Background
Squamous cell carcinoma is the most frequent histologi-
cal type of cancer of the esophagus (ESCC) [1]. It occurs
predominantly in developing countries and is the sixth
most common neoplasia in Brazil [2]. ESCC generally has
a poor prognosis because it is usually in an advanced stage
at the time of diagnosis. Its epidemiological characteristics
suggest the involvement of environmental factors in its
etiology [3-5].
The mortality rate is still high despite the development of
many therapeutic modalities in addition to surgical resec-
tion. Esophagectomy with lymph node dissection has sig-
nificant morbidity and mortality rates [5-7]. Therefore, it
is important to understand the prognostic factors that
determine the most appropriate surgical approach in
order to select patients for target-directed therapies.
The family of epidermal growth factor receptors com-
prises four homologous molecules: EGFR, c-erbB-2, c-
erbB-3 and c-erbB-4. Some reports have suggested that
abnormal activation of kinase activity in these receptors
has an important role in tumor development and progres-
sion in ESCC [8,9]. Activation of these receptors induces
cell migration and aggregation as well as hyperprolifera-
tion and epithelial cell differentiation [1]. The importance
of these receptors has been studied in many malignant
neoplasms, but mainly in breast carcinoma, leading to
specific treatments to inactivate them [10].
Gene amplification has been described in many tumor
types and is associated with poor prognosis [11]. When
identified, gene amplification is an important indicator
for more intensive treatment, mainly in breast and lung
cancer [12-15]. It is analyzed by fluorescence (FISH) or
chromogenic (CISH) in situ hybridization to measure the
gene copy number.
Studies have verified that the HER-2/neu (c-erbB-2) onco-
gene (located on chromosome 17) is amplified and over-
expressed in many tumor types, and have compared these
results with immunohistochemical expression and clin-
icopathological data using Tissue Microarray [16-20] or
conventional slides [21-23]. Amplification and overex-
pression of HER-2/neu (c-erbB-2) predict an especially
poor prognosis in breast cancer.
Few studies have used FISH to evaluate HER-2/neu ampli-
fication in ESCC; these reports show low gene amplifica-
tion frequencies in this tumor [24,25]. Mimura et al.
(2005) found that 11% of cases showed HER-2/neu
amplification, including all cases considered 3+ by immu-
nohistochemical analysis and 3/6 (50%) of those consid-
ered 2+ [24]. These authors also demonstrated that cases
with gene amplification had lower survival rates. A study
by Sunpaweravong et al. (2005) showed gene amplifica-
tion in 2% of cases, but this factor was not associated with
overall survival [26]. Similar results were presented by
Reichelt et al. (2007), in which 5% of the ESCC were pos-
itive for amplification of HER-2/neu; however, amplifica-
tion did not influence prognosis [25].
Although recognition of gene amplification may be a key
factor in therapeutic decision-making, there is a paucity of
data regarding HER-2/neu amplification in ESCC. In this
study, we detect gene amplification of HER-2/neu by flu-
orescence  in situ hybridization and evaluate protein
expression by immunohistochemistry in ESCC. We dis-
cuss the relationship between the clinicopathological fea-
tures of this disease and the prognostic value of HER-2/
neu amplification.
Methods
ESSC cases and specimens
This study was performed with the approval of the Ethics
Committee of Hospital A. C. Camargo, São Paulo, Brazil
(Protocol n. 530/03). It utilized archival formalin-fixed
paraffin-embedded tissues from surgical specimens of 199
ESCC cases treated at Hospital A. C. Camargo between
1980 and 1999. From these 199 cases, 427 samples were
analyzed using the Tissue Microarray (TMA) technique.
The samples were distributed into three TMA paraffin
blocks containing 1 mm cores of 143 samples in each of
two blocks and 141 in a third. One hundred and fifty-
three cases were represented by more than one sample in
the TMA blocks. All samples were spotted in duplicate,
corresponding to different areas of the same original par-
affin block. Slides of 3 μm were obtained by adhesives
specific for the technique (Instrumedics Inc.). The TMA
blocks were constructed with "Manual Tissue Arrayer I"
(Beecher Instruments Inc.).
For all cases we reviewed age, gender, ethnicity, location
of primary tumor, histological grade, extent of infiltration,
lymphatic and venous invasion, and evolution of disease.
The clinicopathological data are summarized in Table 1.
The follow-up time ranged from 1 to 200 months with an
average of 21.8 months. The ages of the 199 patients
selected for this study ranged from 37 to 80 years, with a
mean of 57 years (standard deviation = 9).
Immunohistochemistry
The immunohistochemical reactions were realized by the
streptavidin-biotin-peroxidase complex technique
(StreptABC, DAKO, Denmark). The tissue sections were
deparaffinized and incubated in citrate buffer in a pres-
sure cooker for antigenic retrieval, then endogenous per-
oxidase activity was blocked with 3% H202. The sectionsBMC Cancer 2009, 9:6 http://www.biomedcentral.com/1471-2407/9/6
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were then incubated with polyclonal primary antibodies
against c-erbB-2 (1:500, A0485, DAKO, Denmark). Subse-
quently, they were incubated in secondary biotinylated
antibody from LSAB+ peroxidase Kit (DAKO, K0690,
Denmark), followed by incubation with Streptavidin HRP
(DAKO, Denmark), and were counterstained with Hema-
toxylin.
Immunohistochemical analyses of c-erbB-2 expression
describe the intensity and staining pattern of tumor cells.
Table 1: Clinicopathological findings of ESCC cases selected for this study
Variable Category N (%) Total
Gender Male 161 (80.9) 199
Female 38 (19.1)
Ethnicity Caucasian 148 (74.4) 199
Not Caucasian 42 (21.1)
No data available 9 (4.5)
Tumor location Upper 34 (17.1) 199
Middle 104 (52.3)
Lower 50 (25.1)
No data available 11 (5.5)
Histological grade G1 62 (31.2) 199
G2 93 (46.7)
G3 42 (21.1)
G4 2 (1)
Infiltration level Basal layer 9 (4.5) 199
Muscular 42 (21.1)
Adventitia 148 (74.4)
Lymphatic invasion Not observed 160 (80.4) 199
Present 39 (19.6)
Venous invasion Not observed 58 (29.1) 199
Present 141 (70.9)
pN Negative 107 (53.8) 199
Positive 89 (44.7)
No data available 3 (1.5)
Surgical margins Not committed 6 (3.0) 199
Committed 188 (94.5)
No data available 5 (2.5)
Stage I 6 (3) 199
II 86 (43.2)
III 53 (26.6)
IV 52 (26.1)
No data available 2 (1)
Tumor recurrence Negative 87 (43.7) 199
Positive 110 (55.3)
No data available 2 (1)
Evolution of disease Death from disease 153 (76,9) 199
Alive without disease 7 (3.5)
Alive with disease 1 (0.5)
No follow-up 38 (19.1)BMC Cancer 2009, 9:6 http://www.biomedcentral.com/1471-2407/9/6
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The FDA-recognized test, the Herceptest™ (DAKO),
describes four categories: no staining, or weak staining in
fewer than 10% of the tumor cells (0); weak staining in
part of the membrane in more than 10% of the tumor
cells (1+); complete staining of the membrane with weak
or moderate intensity in more than 10% of the neoplastic
cells (2+); and strong staining in more than 10% (3+).
Each sample was categorized in one of three groups
according to the following criteria: most of the cores had
0 and/or 1+ expression (Negative Group); at least 50% of
the cores had 2+ expression and none had 3+ (Potential
Positive Group); and at least one case had 3+ expression
and none had 0/1+ (Positive Group).
Two slides of each TMA block, separated by about 40 sec-
tions, were subjected to immunohistochemistry. Because
each sample was spotted in duplicate in each TMA block,
there were four immunohistochemical analyses for each
specimen. In addition, because each case could be repre-
sented by more than one sample in the TMA blocks, more
than four cores could be obtained in each case for each
marker.
Dual-color Fluorescence in situ Hybridization
One slide of each TMA block was subjected to hybridiza-
tion reactions. HER2/neu amplification was analyzed
using FISH HER2 PharmDx (Dako, K5331, Denmark),
which contains both fluorescently-labeled HER2/neu
gene and chromosome 17 centromere probes.
In brief, the sections were incubated at 56°C overnight
and deparaffinized by washing in xylene, ethanol and dis-
tilled water. After incubation in 0.2 M HCl at room tem-
perature for 20 minutes they were heat-pretreated in
citrate buffer (2 × SSC, pH 6.0) at 80°C for 1 to 1.5 hours.
They were then digested with pepsin at room temperature
for 8–14 minutes, rinsed in 2 × SSC at room temperature
for 2 minutes and dehydrated in graded ethanol (75, 80,
and 100%) for 2 minutes.
After the HER2/CEN17 probe mix was applied to the
dry slides, the tissue area was coverslipped and sealed
with rubber cement. The slides were then incubated in
hybridizer (Hybridizer Instrument for in situ hybridiza-
tion, DAKO, S2450, Denmark) for denaturation at
82°C for 5 minutes and hybridization at 45°C for
about 18 hours.
Posthybridization washes were performed in urea/0.1 ×
SSX at 45°C for 30 minutes and in 2 × SSC at room tem-
perature for 2 minutes. The slides were dehydrated in
graded ethanol, and after application of 15 μL of mount-
ing medium containing 4',6'-diamidino-2-phenylindole
(DAPI), the tissue area was coverslipped.
FISH analyses were performed according to the HER2
FISH PharmDx (Dako, Denmark) criteria. In each case,
100 non-overlapped, intact interphase tumor nuclei iden-
tified by DAPI staining were evaluated, and gene (red sig-
nal) and CEN17 (green signal) copy numbers in each
nucleus were assessed. The cases were considered to be
amplified when the average copy number ratio, HER2/
CEN17, was ≥ 2.0 in all nuclei evaluated or when the
HER2 signals formed a tight gene cluster. Among the cases
in which the gene was not amplified, samples showing
more than four copies of the HER2 gene and more than
four CEN17 in more than 10% of the tumor cells were
considered to be polysomic for chromosome 17.
Statistical analyses
All statistical analyses were performed using SPSS for Win-
dows 13.0, SPSS Inc. Categorical variables were compared
by the Pearson chi-square test or Fisher's exact test,
depending on the expected values found in the contin-
gency table. The overall survival rates were calculated
using the Kaplan-Meier method and the curves were com-
pared by the log-rank test. In all statistical tests, the alpha
error was set at 5%. The survival period was calculated
from the date of hospital admission to death or the date
of last follow-up.
Results
c-erbB-2 immunohistochemistry
Expression of c-erbB-2 was analyzed in 185 cases of ESCC
according to the membrane staining pattern of the tumor
cells. One hundred and seventeen cases (63.2%) were
negative and 68 (36.8%) were positive, of which 56
(30.3%) were 2+ and 12 (6.5%) were 3+ (Figure 1).
Statistical analysis revealed no significant association
between c-erbB-2 expression and the clinicopathological
findings. The data are summarized in Table 2. Furthermore,
univariate analysis showed that c-erbB-2 expression was not
significantly associated with overall survival (Figure 2).
HER-2/neu amplification
The same cases evaluated by immunohistochemistry were
also examined using FISH. Of the 199 cases, 47 were suit-
able for evaluating gene amplification. In the remaining
138 cases there was no HER2 gene or CEN17 hybridiza-
tion signal, or these samples showed collapsed nuclei.
Gene amplification was found in nine (19.1%) of the
cases; 38 (80.9%) showed no amplification (Figure 3).
Among the cases in which amplification was not found,
five (13.2%) had polysomy of chromosome 17.
When the FISH results were compared with the c-erbB-2
immunohistochemical data, six (66.7%) of the nine cases
with gene amplification showed positive expression (3+
IHC) for this protein. Three (33.3%) were not availableBMC Cancer 2009, 9:6 http://www.biomedcentral.com/1471-2407/9/6
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for immunohistochemistry, as shown in Table 3. None of
the amplified cases was negative or had 2+ protein expres-
sion as assessed by immunohistochemistry. Otherwise,
among the cases in which gene amplification was not
found, 11 (28.9%) and 15 (39.5%) were 0/1+ and 2+ by
IHC, respectively. However, six (15.8%) cases lacking
gene amplification showed positive (3+ IHC) expression.
Of the five cases showing polysomy of chromosome 17,
two (40%) were 3+ IHC, two (40%) were 2+, and one
(20%) was negative (0/1+ IHC).
In view of the low number of cases studied, it was not pos-
sible to compare the FISH results and clinicopathological
findings statistically (data not shown).
According to the Kaplan-Meier method, there was a signif-
icant difference (p = 0.003) between the survival rates
when cases with and without gene amplification were
compared. Cases demonstrating gene amplification
showed the worst survival rates (Figure 4).
Discussion
The TMA technique provides a high-throughput means of
evaluating genetic alterations in a great number of tumor
samples. Sections from TMA blocks can be used for FISH,
allowing gene amplification to be evaluated in hundreds
of tumor samples on a single slide.
Immunohistochemical analysis showed that 36.8% of the
cases were positive for expression of c-erbB-2. The few
studies reporting c-erbB-2 expression in ESCC show dis-
crepant frequencies ranging from 0 to 64% [27-31]. This
variability may have resulted from differences in immu-
nohistochemical protocols, different antibody sources
used by the different authors, or different criteria for eval-
uating expression.
Immunohistochemistry showing c-erbB-2 membrane staining in ESCC Figure 1
Immunohistochemistry showing c-erbB-2 membrane staining in ESCC. (a) sample negative for expression of this 
protein, 400×; (b) positive case 2+, 400×; (c) and (d) positive cases 3+, 400×.
AB
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We found no significant association between c-erbB-2
expression and the clinicopathological findings. Most
reported studies agree with our results and report no influ-
ence of c-erbB-2 expression on ESSC prognosis
[27,28,32]; however, a study performed by Lam et al.
(1998) demonstrated a significant association between
this protein and histological grade [29], and a recent study
showed that c-erbB-2 overexpression is associated with
lower rates of survival [33].
The reported frequencies of HER-2/neu amplification in
ESCC vary from 2 to 11% of cases [24-26]. This variability
may have resulted from differences in tissue preparation,
probes, and the methods used to evaluate the alterations.
Our study demonstrated gene amplification in 20% of cases,
higher than any previously reported frequency [24-26].
In this study, 199 cases were subjected to immunohisto-
chemical evaluation; 47 were also suitable for FISH anal-
ysis. The remaining cases had complete loss of tumor
cores from the TMA or fewer than 100 tumor nuclei were
available for evaluation, or the samples were under- or
over-digested, resulting in absence of hybridization sig-
nals and loss of cell and nuclear morphology.
Table 2: Association between c-erbB-2 expression and clinicopathological data in 185 cases of ESCC analyzed by TMA
Variables Category c-erbB-2
Negative
[0 and 1+]
(%)
Positive
[2 and 3+]
(%)
Total p value
Gender Male 97 (82.9) 52 (76.5) 149 0.337
Female 20 (17.1) 16 (23.5) 36
Age < 60 years 61 (54.5) 46 (69.7) 107 0.057
≥ 60 years 51 (45.5) 20 (30.3) 71
Ethnicity Caucasian 84 (77.1) 52 (77.6) 136 1.000
No Caucasian 25 (22.9) 15 (22.4) 40
Tumor location Upper 18 (16.2) 12 (18.8) 30 0.781
Middle 65 (58.6) 34 (53.1) 99
Lower 28 (25.2) 18 (28.1) 46
Histological grade G1+G2 87 (74.4) 57 (83.8) 144 0.147
G3+G4 30 (25.6) 11 (16.2) 41
Infiltration level Basal layer 5 (4.3) 0 (0) 5 NA
Muscular 22 (18.8) 17 (25) 39
Adventitia 90 (76.9) 51 (75) 141
Lymphatic invasion Not observed 30 (25.6) 19 (27.9) 49 0.733
Present 87 (74.4) 49 (72.1) 136
Venous invasion Not observed 95 (81.2) 54 (79.4) 149 0.848
Present 22 (18.8) 14 (20.6) 36
pN Negative 63 (53.8) 36 (52.9) 99 1.000
Positive 54 (46.2) 32 (47.1) 86
Surgical margins Not committed 110 (95.7) 67 (98.5) 177 NA
Committed 5 (4.3) 1 (1.5) 6
Stage 1+2 58 (49.6) 27 (39.7) 85 0.222
3+4 59 (50.4) 41 (60.3) 100
Recurrence Negative 49 (42.6) 28 (41.8) 77 1.000
Positive 66 (57.4) 39 (58.2) 105
NA: not availableBMC Cancer 2009, 9:6 http://www.biomedcentral.com/1471-2407/9/6
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One of the problems with the TMA technique for FISH is
that fixatives such as formalin preserve the tissue structure
by forming cross-bridges, which reduce the access of the
probes to their targets. Another important challenge in
FISH analysis is to standardize the tissue digestion on
TMA: the hundreds of samples on one slide may differ in
tissue type, fixation methods and age. Successful FISH
analysis depends on a pretreatment protocol that is con-
sistent in the use of digesting agents (sodium thiocyanate,
pepsin or proteinase K) as well as appropriate conditions
(concentration, temperature and time of incubation) to
unmask the target DNA and optimize hybridization. The
presence of hundreds of tissue cores on a TMA slide com-
pounds the difficulty of optimization; a given set of con-
ditions appropriate for some samples may over- or under-
digest others.
Among the 47 cases suitable for FISH analysis, only those
that were 3+ positive for immunohistochemistry showed
HER-2/neu amplification (66.7%). The remaining 33.3%
of the amplified cases were not suitable for immunohisto-
chemical evaluation because there were no tumor cells in
the cores or the tissue cores were completely lost from the
TMA.
Mimura et al. (2005) found results similar to those of the
present study, but as well as all the 3+ cases, 50% of their
2+ cases also showed gene amplification [24]. Another
study reported a significant association between gene
amplification and protein overexpression in 70% of 3+
and in 30% of 2+ amplified cases [25]. In contrast to these
results, Sunpaweravong et al. (2005) found no significant
association between gene amplification and immunohis-
tochemical expression; the one case positive for amplifica-
tion did not overexpress c-erbB-2 [26].
With respect to overall survival, our data are in agreement
with the findings of Mimura et al. (2005), showing signifi-
cant differences in survival rates in cases with gene amplifi-
cation [24]. The significant association between HER-2/neu
amplification and lower survival rate indicates a role for
this gene alteration analysis in the prognosis of ESCC cases.
Our results did not show that c-erbB-2 expression has a
prognostic value in ESCC. In contrast, Mimura et al.
Overall survival according to HER-2/neu expression Figure 2
Overall survival according to HER-2/neu expression. 
c-erbB-2 expression in 185 cases of ESCC.
Analysis of HER-2/neu gene amplification in 47 cases of ESCC Figure 3
Analysis of HER-2/neu gene amplification in 47 cases of ESCC. (a) Samples with no amplification; (b) case considered 
amplified. In detail, nucleus shows ratio ≥ 2 and (c) gene amplification showing cluster pattern. 1000×.BMC Cancer 2009, 9:6 http://www.biomedcentral.com/1471-2407/9/6
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(2005) found that the survival rate in the HER-2-positive
group was significantly worse than that in the HER-2-neg-
ative group. Despite the concordance between the FISH
and immunohistochemistry results, only the presence of
gene amplification seems to affect prognosis in ESCC.
Unlike the previous report, FISH and immunohistochem-
istry analyses were performed on different numbers of
cases (47 and 185, respectively) in the current study,
which could have contributed to the discrepancy between
the two studies [24]. Further studies with more cases are
necessary for a better understanding of the influence of
this gene on ESCC progression.
Tumors showing c-erbB-2 overexpression but not gene
amplification could occur because of transcriptional or
post-transcriptional alterations, polysomy of chromo-
some 17 or even technical problems such as the high sen-
sitivity of the immunohistochemical procedure. In the
current study, the assessment of the number of copies of
chromosome 17 showed that some 3+ cases could have
resulted from polysomy 17. Transcriptional or post-tran-
scriptional alterations were not evaluated in the present
study; further studies employing other techniques such as
RT-PCR would be required. Alternatively, the greater sen-
sitivity of immunohistochemistry compared with FISH
could also account for this result.
Nonetheless, our results corroborate previous reports that
most c-erbB-2 overexpression is caused by gene amplifica-
tion [14]. There is a consensus that c-erbB-2 expression must
be evaluated initially by immunohistochemistry and, if the
results are not conclusive, FISH should be performed. Such a
practice has been standard procedure to assist in making
therapeutic decisions in breast and lung cancer cases [12-15].
Trastuzumab (Herceptin) prolongs survival in metastatic
breast cancer patients whose tumours overexpress the
HER2/neu protein [34]. Similarly, patients with ESCC
having HER-2/neu gene amplification might also benefit
from treatment with Trastuzumab, since HER-2/neu
amplification indicates a group of cases in which this type
of treatment could improve the prognosis [24,35].
Conclusion
Our results indicate that HER-2/neu gene amplification is
an important prognostic indicator in ESCC. Further stud-
ies with more cases and including additional techniques
are necessary to verify other molecular alterations
involved in tumor progression, thus assisting in the devel-
opment of new therapies for ESCC.
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Table 3: Comparison of gene amplification analysis and immunohistochemical results of HER-2/neu in 47 cases of ESCC
IHC
c-erbB-2
FISH HER-2
Not Amplified (%) Polysomy 17 (%) Amplified (%) Total
0/1+ 10 (30.3) 1 (20) 0 (0) 11
2+ 13 (39.4) 2 (40) 0 (0) 15
3+ 4 (12.1) 2 (40) 6 (66.7) 12
NA 6 (18.2) 0 (0) 3 (33.3) 9
Total 33 (100) 5 (100) 9 (100) 47
NA: not available
Overall survival according to HER-2/neu amplification Figure 4
Overall survival according to HER-2/neu amplifica-
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